NIH awards multimillion-dollar grant to fund expanded NUZ-001 access program in ALS
The US National Institutes of Health (NIH) has awarded a multimillion-dollar, multiyear grant to the Sean M. Healey & AMG Center for ALS at Mass General Brigham to fund an Expanded Access Protocol (EAP) for NUZ-001 in amyotrophic lateral sclerosis (ALS), with Neurizon Therapeutics receiving funding as subawardee under NIH Project Number 1U01NS153995-01. Critically, the EAP is fully funded through the NIH award, covering all EAP-related drug supply, manufacturing, and specified regulatory costs associated with Neurizon’s participation.
The program is expected to provide up to 200 ALS patients who are otherwise ineligible for clinical trials with access to NUZ-001 for up to 96 weeks. Running in parallel with Regimen I of the ongoing Phase 2/3 HEALEY ALS Platform Trial (approximately 250 participants), participant enrolment is targeted to commence by Q1 CY27, with Phase 2/3 topline results expected in late Q2 CY27.
The Regimen I expansion from 160 to 240 participants was completed without any change to funding requirements, with philanthropic contributions from the Healey Center and the Australian R&D Tax Incentive covering incremental costs, reflecting the same cost-offset model that now extends to the NIH-funded EAP.
When big ASX news breaks, our subscribers know first
Program structure and what the EAP means for NUZ-001’s development
Roles and responsibilities
The Healey & AMG Center will lead the clinical and operational execution of the EAP, including site activation, participant recruitment, and data collection. Neurizon will serve as regulatory sponsor and IND holder, and will be responsible for supplying NUZ-001. These roles are distinct and should not be conflated.
The program is expected to be conducted through approximately 20 physical ALS clinical trial sites alongside a national virtual study site, providing potential access across all 50 US states. The virtual model is specifically designed to facilitate participation for people living with ALS who may otherwise have difficulty accessing clinical research, including those in rural and underserved communities.
Data this program will generate
The EAP is designed to generate long-term real-world data from a broader ALS population than is typically represented in randomised clinical trials. The data collected will complement the controlled efficacy and safety evidence being generated through the Phase 2/3 HEALEY ALS Platform Trial, building a richer evidence base without replacing the controlled study. Key data types the EAP is expected to collect include:
- Long-term safety and tolerability
- Survival data
- ALS-specific functional and respiratory measures (ALSFRS-R and slow vital capacity)
- Patient-reported outcomes
- Exploratory biomarkers
From an investment standpoint, this expands Neurizon’s long-term safety database, strengthening the data package available for any future regulatory or commercial pathway.
What is expanded access — and why it matters for ALS investors
Expanded Access, also referred to as Compassionate Use, is a US FDA pathway that allows patients with serious or life-threatening conditions to access investigational therapies that have not yet received FDA approval, where participation in an appropriate clinical trial is not available. This is a recognised and structured regulatory mechanism, not an informal arrangement.
For investors, EAP data carries both commercial and regulatory relevance. Real-world safety and survival data collected from a broader, more diverse patient population complements the controlled randomised trial data and can strengthen an eventual regulatory submission. The EAP population (patients ineligible for clinical trials) is a distinct group from the Phase 2/3 trial participants, meaning the program meaningfully expands NUZ-001’s clinical footprint across two different patient populations simultaneously.
Dr Sabrina Paganoni, Healey & AMG Center
“Expanded Access Programs provide an important opportunity for people living with ALS who are not otherwise eligible for clinical trials to access investigational products. We are grateful to the NIH for supporting this effort and for helping advance opportunities for research in ALS.”
The geographic reach of the program further amplifies this footprint. By combining physical trial sites with a national virtual model, the EAP is structured to capture real-world data from patient populations that controlled trials rarely reach.
Key milestones and what investors should watch
With enrolment targeted to begin in Q1 CY27 and Phase 2/3 topline results expected in late Q2 CY27, the two programs are closely aligned on timeline. The EAP’s continuation beyond topline results is contingent on a positive Phase 2/3 outcome.
HEALEY ALS Platform Trial enrolment completed ahead of schedule with 250 participants across 78 US sites, a record pace for the trial network that pulled the topline efficacy and safety readout forward to late Q2 CY2027.
| Milestone | Target Timing | Program | Significance |
|---|---|---|---|
| EAP enrolment commences | Q1 CY27 | EAP | First patients into expanded access |
| Phase 2/3 topline results | Late Q2 CY27 | HEALEY Platform Trial | Primary efficacy readout |
| EAP continuation decision | Post Q2 CY27 | EAP | Contingent on positive Phase 2/3 outcome |
Sergio Duchini, Interim Executive Chairman
“…The EAP will also significantly expand our long-term safety database and generate valuable biomarker, survival and real-world clinical data from a broader ALS population.”
For investors tracking the NUZ-001 development program, the key takeaways from this announcement are:
- The NIH grant covers drug supply, manufacturing, and specified regulatory and pharmacovigilance costs associated with the company’s participation.
- Expanded clinical dataset — the EAP is expected to generate long-term safety, survival, biomarker, and real-world clinical data that complements the Phase 2/3 trial evidence base.
- 50-state US reach — the combination of approximately 20 physical sites and a national virtual site provides potential access across all US states, including rural and underserved communities.
- Aligned timeline — EAP enrolment is targeted to begin in Q1 CY27, with Phase 2/3 topline results expected in late Q2 CY27, positioning both programs to deliver meaningful data within a defined window.
Don’t Miss the Next ASX Healthcare Catalyst
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at Big News Blast to start receiving real-time coverage today.